North America Pharmacovigilance and Drug Safety Software Market 2021-2031 by Functionality (Adverse Event Reporting, Drug Safety Audits, Issue Tracking, Fully Integrated), Clinical Phase (Pre-clinical, Phase I-IV), Method, Delivery Mode (On-premise, On-demand), Indication, End User (Pharma and Biotech Companies, CROs, BPOs, Others), and Country: Trend Forecast and Growth Opportunity

1 Introduction 8
1.1 Industry Definition and Research Scope 8
1.1.1 Industry Definition 8
1.1.2 Research Scope 9
1.2 Research Methodology 12
1.2.1 Overview of Market Research Methodology 12
1.2.2 Market Assumption 13
1.2.3 Secondary Data 13
1.2.4 Primary Data 13
1.2.5 Data Filtration and Model Design 14
1.2.6 Market Size/Share Estimation 15
1.2.7 Research Limitations 16
1.3 Executive Summary 17
2 Market Overview and Dynamics 20
2.1 Market Size and Forecast 20
2.1.1 Impact of COVID-19 on World Economy 21
2.1.2 Impact of COVID-19 on the Market 25
2.2 Major Growth Drivers 27
2.3 Market Restraints and Challenges 32
2.4 Emerging Opportunities and Market Trends 35
2.5 Porter"s Fiver Forces Analysis 39
3 Segmentation of North America Market by Functionality 43
3.1 Market Overview by Functionality 43
3.2 Adverse Event Reporting Software 45
3.3 Drug Safety Audits Software 46
3.4 Issue Tracking Software 47
3.5 Fully Integrated Software 48
4 Segmentation of North America Market by Clinical Phase 49
4.1 Market Overview by Clinical Phase 49
4.2 Pre-clinical 51
4.3 Phase I 52
4.4 Phase II 53
4.5 Phase III 54
4.6 Phase IV 55
5 Segmentation of North America Market by Method 56
5.1 Market Overview by Method 56
5.2 Spontaneous Reporting 58
5.3 Intensified ADR Reporting 59
5.4 Targeted Spontaneous Reporting 60
5.5 Cohort Event Monitoring 61
5.6 EHR Mining 62
6 Segmentation of North America Market by Delivery Mode 63
6.1 Market Overview by Delivery Mode 63
6.2 On-premise Delivery 65
6.3 On-demand Delivery 66
7 Segmentation of North America Market by Indication 67
7.1 Market Overview by Indication 67
7.2 Oncology 69
7.3 Respiratory Disorders 70
7.4 Cardiology 71
7.5 Neurology 72
7.6 Immunology 73
7.7 Pain Management 74
7.8 Other Indications 75
8 Segmentation of North America Market by End User 76
8.1 Market Overview by End User 76
8.2 Pharmaceutical and Biotechnology Companies 78
8.3 Contract Research Organizations (CROs) 79
8.4 Business Process Outsourcing Firms (BPOs) 80
8.5 Other End Users 81
9 North America Market 2021-2031 by Country 82
9.1 Overview of North America Market 82
9.2 U.S. 85
9.3 Canada 88
9.4 Mexico 90
10 Competitive Landscape 92
10.1 Overview of Key Vendors 92
10.2 New Product Launch, Partnership, Investment, and M&A 95
10.3 Company Profiles 96
Ab Cube 96
Accenture PLC 98
ArisNorth America LLC 99
Cognizant Technology Solutions Corporation 100
Ennov Solutions Inc. 101
Extedo GmbH 102
Honeywell International Inc. (Sparta Systems Inc.) 103
IQVIA Inc. 104
Max Application 105
Oracle Corporation 106
Sarjen Systems Pvt. Ltd. 107
United BioSource LLC 108
Veeva Systems Inc. 109
Wipro Limited 110
RELATED REPORTS 111

List of Tables:

Table 1. Snapshot of North America Pharmacovigilance and Drug Safety Software Market in Balanced Perspective, 2021-2031 18
Table 2. World Economic Outlook, 2021-2031 22
Table 3. World Economic Outlook, 2021-2023 23
Table 4. Main Product Trends and Market Opportunities in North America Pharmacovigilance and Drug Safety Software Market 35
Table 5. North America Pharmacovigilance and Drug Safety Software Market by Functionality, 2021-2031, $ mn 43
Table 6. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase, 2021-2031, $ mn 49
Table 7. North America Pharmacovigilance and Drug Safety Software Market by Method, 2021-2031, $ mn 56
Table 8. North America Pharmacovigilance and Drug Safety Software Market by Delivery Mode, 2021-2031, $ mn 63
Table 9. North America Pharmacovigilance and Drug Safety Software Market by Indication, 2021-2031, $ mn 67
Table 10. North America Pharmacovigilance and Drug Safety Software Market by End User, 2021-2031, $ mn 76
Table 11. North America Pharmacovigilance and Drug Safety Software Market by Country, 2021-2031, $ mn 83
Table 12. U.S. Pharmacovigilance and Drug Safety Software Market by Functionality, 2021-2031, $ mn 87
Table 13. U.S. Pharmacovigilance and Drug Safety Software Market by Delivery Mode, 2021-2031, $ mn 87
Table 14. U.S. Pharmacovigilance and Drug Safety Software Market by End User, 2021-2031, $ mn 87
Table 15. Canada Pharmacovigilance and Drug Safety Software Market by Functionality, 2021-2031, $ mn 89
Table 16. Canada Pharmacovigilance and Drug Safety Software Market by Delivery Mode, 2021-2031, $ mn 89
Table 17. Canada Pharmacovigilance and Drug Safety Software Market by End User, 2021-2031, $ mn 89
Table 18. Mexico Pharmacovigilance and Drug Safety Software Market by Functionality, 2021-2031, $ mn 91
Table 19. Mexico Pharmacovigilance and Drug Safety Software Market by Delivery Mode, 2021-2031, $ mn 91
Table 20. Mexico Pharmacovigilance and Drug Safety Software Market by End User, 2021-2031, $ mn 91
Table 21. Ab Cube: Company Snapshot 96
Table 22. Ab Cube: Business Segmentation 97
Table 23. Ab Cube: Product Portfolio 97

List of Figures:

Figure 1. Research Method Flow Chart 12
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 15
Figure 3. North America Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2021-2031 17
Figure 4. North America Pharmacovigilance and Drug Safety Software Market, 2021-2031, $ mn 20
Figure 5. Impact of COVID-19 on Business 25
Figure 6. Primary Drivers and Impact Factors of North America Pharmacovigilance and Drug Safety Software Market 27
Figure 7. Percentage of Trial Participants by Country, 2015-2019 30
Figure 8. World Drug Discovery Market, 2019-2030, $ mn 31
Figure 9. Primary Restraints and Impact Factors of North America Pharmacovigilance and Drug Safety Software Market 32
Figure 10. Investment Opportunity Analysis 36
Figure 11. Porter"s Fiver Forces Analysis of North America Pharmacovigilance and Drug Safety Software Market 39
Figure 12. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Functionality, 2021-2031, % of Revenue 44
Figure 13. North America Addressable Market Cap in 2022-2031 by Functionality, Value ($ mn) and Share (%) 44
Figure 14. North America Pharmacovigilance and Drug Safety Software Market by Functionality: Adverse Event Reporting Software, 2021-2031, $ mn 45
Figure 15. North America Pharmacovigilance and Drug Safety Software Market by Functionality: Drug Safety Audits Software, 2021-2031, $ mn 46
Figure 16. North America Pharmacovigilance and Drug Safety Software Market by Functionality: Issue Tracking Software, 2021-2031, $ mn 47
Figure 17. North America Pharmacovigilance and Drug Safety Software Market by Functionality: Fully Integrated Software, 2021-2031, $ mn 48
Figure 18. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase, 2021-2031, % of Sales Revenue 50
Figure 19. North America Addressable Market Cap in 2022-2031 by Clinical Phase, Value ($ mn) and Share (%) 50
Figure 20. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Pre-clinical, 2021-2031, $ mn 51
Figure 21. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase I, 2021-2031, $ mn 52
Figure 22. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase II, 2021-2031, $ mn 53
Figure 23. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase III, 2021-2031, $ mn 54
Figure 24. North America Pharmacovigilance and Drug Safety Software Market by Clinical Phase: Phase IV, 2021-2031, $ mn 55
Figure 25. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Method, 2021-2031, % of Sales Revenue 57
Figure 26. North America Addressable Market Cap in 2022-2031 by Method, Value ($ mn) and Share (%) 57
Figure 27. North America Pharmacovigilance and Drug Safety Software Market by Method: Spontaneous Reporting, 2021-2031, $ mn 58
Figure 28. North America Pharmacovigilance and Drug Safety Software Market by Method: Intensified ADR Reporting, 2021-2031, $ mn 59
Figure 29. North America Pharmacovigilance and Drug Safety Software Market by Method: Targeted Spontaneous Reporting, 2021-2031, $ mn 60
Figure 30. North America Pharmacovigilance and Drug Safety Software Market by Method: Cohort Event Monitoring, 2021-2031, $ mn 61
Figure 31. North America Pharmacovigilance and Drug Safety Software Market by Method: EHR Mining, 2021-2031, $ mn 62
Figure 32. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Delivery Mode, 2021-2031, % of Revenue 64
Figure 33. North America Addressable Market Cap in 2022-2031 by Delivery Mode, Value ($ mn) and Share (%) 64
Figure 34. North America Pharmacovigilance and Drug Safety Software Market by Delivery Mode: On-premise Delivery, 2021-2031, $ mn 65
Figure 35. North America Pharmacovigilance and Drug Safety Software Market by Delivery Mode: On-demand Delivery, 2021-2031, $ mn 66
Figure 36. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Indication, 2021-2031, % of Revenue 68
Figure 37. North America Addressable Market Cap in 2022-2031 by Indication, Value ($ mn) and Share (%) 68
Figure 38. North America Pharmacovigilance and Drug Safety Software Market by Indication: Oncology, 2021-2031, $ mn 69
Figure 39. North America Pharmacovigilance and Drug Safety Software Market by Indication: Respiratory Disorders, 2021-2031, $ mn 70
Figure 40. North America Pharmacovigilance and Drug Safety Software Market by Indication: Cardiology, 2021-2031, $ mn 71
Figure 41. North America Pharmacovigilance and Drug Safety Software Market by Indication: Neurology, 2021-2031, $ mn 72
Figure 42. North America Pharmacovigilance and Drug Safety Software Market by Indication: Immunology, 2021-2031, $ mn 73
Figure 43. North America Pharmacovigilance and Drug Safety Software Market by Indication: Pain Management, 2021-2031, $ mn 74
Figure 44. North America Pharmacovigilance and Drug Safety Software Market by Indication: Other Indications, 2021-2031, $ mn 75
Figure 45. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by End User, 2021-2031, % of Revenue 76
Figure 46. North America Addressable Market Cap in 2022-2031 by End User, Value ($ mn) and Share (%) 77
Figure 47. North America Pharmacovigilance and Drug Safety Software Market by End User: Pharmaceutical and Biotechnology Companies, 2021-2031, $ mn 78
Figure 48. North America Pharmacovigilance and Drug Safety Software Market by End User: Contract Research Organizations (CROs), 2021-2031, $ mn 79
Figure 49. North America Pharmacovigilance and Drug Safety Software Market by End User: Business Process Outsourcing Firms (BPOs), 2021-2031, $ mn 80
Figure 50. North America Pharmacovigilance and Drug Safety Software Market by End User: Other End Users, 2021-2031, $ mn 81
Figure 51. Breakdown of North America Pharmacovigilance and Drug Safety Software Market by Country, 2021 and 2031, % of Revenue 83
Figure 52. Contribution to North America 2022-2031 Cumulative Market by Country, Value ($ mn) and Share (%) 84
Figure 53. U.S. Pharmacovigilance and Drug Safety Software Market, 2021-2031, $ mn 86
Figure 54. Canada Pharmacovigilance and Drug Safety Software Market, 2021-2031, $ mn 88
Figure 55. Pharmacovigilance and Drug Safety Software Market in Mexico, 2021-2031, $ mn 90
Figure 56. Growth Stage of North America Pharmacovigilance and Drug Safety Software Industry over the Forecast Period 92

Selected Key Players:
Ab Cube
Accenture PLC
ArisGlobal LLC
Cognizant Technology Solutions Corporation
Ennov Solutions Inc.
Extedo GmbH
Honeywell International Inc. (Sparta Systems Inc.)
IQVIA Inc.
Max Application
Oracle Corporation
Sarjen Systems Pvt. Ltd.
United BioSource LLC
Veeva Systems Inc.
Wipro Limited
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)